Soluble GPV Polypeptide for Selective Thrombus Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-platelet therapies for preventing thrombotic events are limited by the increased risk of bleeding and are ineffective for a subset of patients, highlighting the need for novel anti-platelet strategies that can selectively inhibit thrombus formation without affecting hemostasis.
Innovation Solution
Development of a soluble polypeptide comprising a modified glycoprotein V (GPV) with antithrombotic activity, which can be administered to prevent thrombotic diseases without affecting bleeding time, by utilizing a truncated form of GPV that lacks a functional transmembrane domain and is recombinantly expressed for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-platelet therapies are used to prevent thrombotic events, then thrombus formation is inhibited, but bleeding risk increases
Solution Approach 1:
The invention segments the GPV protein into a soluble form lacking the transmembrane domain, separating the antithrombotic function from the hemostatic function. This segmentation allows selective inhibition of thrombus formation on foreign surfaces without affecting physiological hemostasis, thereby resolving the contradiction between preventing thrombosis and avoiding bleeding complications
Solution Approach 2:
The soluble GPV polypeptide acts as an intermediary that specifically binds to vWF on foreign surfaces, blocking platelet adhesion to artificial surfaces without interfering with normal platelet function in physiological conditions. This intermediary approach selectively targets the harmful thrombotic effect while preserving normal hemostasis
2Reliability
If current anti-platelet therapies are used, then some patients are protected from thrombotic events, but a subset of patients remains refractory to treatment
Solution Approach 1:
The invention extracts the critical adhesion-blocking function from the complex platelet activation pathway by using soluble GPV that specifically targets vWF-GPV interactions. This extracted mechanism provides a novel therapeutic approach that is effective in patients refractory to conventional anti-platelet therapies, improving adaptability across different patient populations
Data Source
AI summary
A soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain for use in the treatment or prevention of a thrombotic disease in a subject, said treatment or prevention comprising administering to the subject an effective amount of said soluble polypeptide.